American Diabetes Association (ADA) 2026

The intersection of cardiovascular and metabolic diseases is one of the most consequential frontiers in drug development today, as risk is increasingly understood to accumulate across interconnected systems. Conditions such as type 2 diabetes, obesity, dyslipidemia, metabolic dysfunction-associated steatohepatitis (MASH) and metabolic syndromes are significantly associated with increased cardiovascular risk. Addressing them requires integrated expertise that spans multiple therapeutic disciplines. 

At Syneos Health we combine specialized therapeutic depth, regulatory acumen and operational excellence to help you navigate every stage of diabetes and cardiometabolic drug development. Our cross-therapeutic model means sponsors benefit from unified trial design expertise, shared site networks with cardiometabolic patient populations and integrated regulatory strategy – supporting earlier, more confident decisions from feasibility through pivotal outcomes studies. 

Meet with Us

Meet with us onsite at Booth #2125 to explore how we help sponsors manage complexity and reduce risk to advance cardiometabolic innovation, from lab to life. 

Additional Resources:

Want to learn more? Explore Insights Hub for our latest perspectives, subscribe to our podcast, or click the resources below: 

Meet with us at ADA 2026